Publisher
Springer Science and Business Media LLC
Reference25 articles.
1. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106(10):2258–2266.
https://doi.org/10.1002/cncr.21847
2. Chirivella I, Bermejo B, Insa A, Perez-Fidalgo A, Magro A, Rosello S, Garcia-Garre E, Martin P, Bosch A, Lluch A (2009) Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. Breast Cancer Res Treat 114(3):479–484.
https://doi.org/10.1007/s10549-008-0018-1
3. Radosavljevic D, Golubicic I, Gavrilovic D, Kezic I, Jelic S (2009) Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer? J BUON 14(2):203–209
4. Bosly A, Bron D, Van Hoof A, De Bock R, Berneman Z, Ferrant A, Kaufman L, Dauwe M, Verhoef G (2008) Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol 87(4):277–283.
https://doi.org/10.1007/s00277-007-0399-y
5. Jenkins P, Freeman S (2009) Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer. Annals of oncology : official journal of the European Society for. Med Oncol 20(1):34–40.
https://doi.org/10.1093/annonc/mdn560